| Texto completo | |
| Autor(es): Mostrar menos - |
Garcia-Junior, M. A.
;
Grosche, V. R.
;
Palmeira, L. S.
;
Teles, C.
;
Ferreira, G. M.
;
Martins, D. O. S.
;
Guevara-Vega, M.
;
Carneiro, M. G.
;
Abuna, R. P. F.
;
Martins, M. M.
;
Rahal, P.
;
da Silva, J. S.
;
Azevedo, V. A. de Carvalho
;
de Paiva, R. E. F.
;
Vitorino, R. M. P.
;
Cunha, T. M.
;
Andrade, B. S.
;
Bergamini, F. R. G.
;
Jardim, A. C. G.
;
Sabino-Silva, R.
Número total de Autores: 20
|
| Tipo de documento: | Artigo Científico |
| Fonte: | JOURNAL OF DENTAL RESEARCH; v. N/A, p. 9-pg., 2025-08-16. |
| Resumo | |
To replicate, SARS-CoV-2 requires its receptor-binding domain (RBD) motif in the Spike protein to interact with specific cellular receptors, such as angiotensin-converting enzyme 2 (ACE2), in human cells. Hence, we aimed to select high-affinity naturally expressed salivary peptides by bioinformatics to assess their potential to block the Spike-RBD/ACE2 interaction in vitro and to evaluate their SARS-CoV-2 antiviral performance. We designed a pipeline with 2,193 salivary peptides and performed molecular docking with 298 peptides using BLASTp. In silico molecular docking was evaluated using HPEPDOCK and validated by molecular dynamics with GROMACS-2020.3 against crystallographed Wuhan wild-type SARS-CoV-2 (SARS-CoV-2WT) Spike-RBD, and the 4 best-performing peptides were redocked against Gamma, Delta, and Omicron Spike-RBD. These 4 selected peptides were synthesized, and antiviral activity was evaluated using VSV-eGFP-SARS-CoV-2 pseudotyped virus and SARS-CoV-2WT. Finally, we evaluated the inhibition of cell death in SARS-CoV-2WT and viral replication inhibition of Gamma and Omicron variants by synthetic mimotopes of salivary peptides by quantifying viral titers using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Salivary peptides SalivaPep1, SalivaPep2, SalivaPep3, and SalivaPep4 had higher binding energy to SARS-CoV-2WT-Spike-RBD, and their effects were maintained against variants, suggesting salivary peptide interactions with SARS-CoV-2. The VSV-eGFP-SARS-CoV-2 infection inhibition rates of selected salivary peptides ranged from 67.5% to 37.6%, respectively, at about 100% cell viability. SalivaPep1, SalivaPep2, and SalivaPep3 reduced cell death resulting from viral replication against SARS-CoV-2WT. Lastly, RT-qPCR showed up to a 74.9% decrease in viral copies against the Gamma variant and 62.5% against the Omicron variant by the treatment with SalivaPep3 and SalivaPep2, derived from salivary Ataxin-1 and Statherin, respectively. The presented bioinformatics workflow was profitable to select on-demand naturally occurring salivary peptides with confirmed antiviral properties in SARS-CoV-2WT, Gamma, and Omicron variants by synthetic mimotopes of salivary peptides, with potential application to prophylactic, diagnostic and therapeutic strategies toward COVID-19. (AU) | |
| Processo FAPESP: | 18/21537-6 - Aplicações de ligantes imínicos polidentados na modulação da reatividade de íons cobre em doenças relacionadas a inflamação e em reações de acoplamento bio-ortogonais |
| Beneficiário: | Raphael Enoque Ferraz de Paiva |
| Modalidade de apoio: | Bolsas no Brasil - Pós-Doutorado |